Simbie AI vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 41)
Simbie AI logo

Simbie AI

EmergingHealthcare

General

SF EHR-integrated AI voice agent for independent medical practices handling scheduling and insurance verification; YC W25 $500K at 83x revenue growth reducing staff-to-physician ratios by one-third.

AI VisibilityBeta
Overall Score
C41
Category Rank
#351 of 596
AI Consensus
74%
Trend
down
Per Platform
ChatGPT
46
Perplexity
36
Gemini
44

About

Simbie AI is a San Francisco-based healthcare technology company developing EHR-integrated AI voice agents that serve as 24/7 multilingual administrative staff for independent medical practices — handling scheduling, insurance verification, prescription refill requests, patient communications, and clinical administrative tasks that currently require front-desk staff handling hundreds of calls daily. Founded by Dr. Natalia Khosla and Rachel O'Driscoll and backed by Y Combinator (W25) with $500,000 raised, Simbie achieved 83x revenue growth since its January 2025 launch with zero churn, reducing staff-to-physician ratios by one-third and recovering 10-20% of revenue previously lost to missed calls.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

41
Overall Score
90
#351
Category Rank
#2
74
AI Consensus
83
down
Trend
stable
46
ChatGPT
92
36
Perplexity
93
44
Gemini
89
44
Claude
96
38
Grok
95

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.